Guggenheim Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5

Benzinga Newsdesk www.benzinga.com Neutral 46.9%

Neg 0% Neu 46.9% Pos 0%

Guggenheim analyst Michael Schmidt maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $12 to $5.